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Abstract
Background: It is generally agreed that in high transmission areas, pregnant women have acquired a partial
immunity to malaria and when infected they present few or no symptoms. However, longitudinal cohort studies
investigating the clinical presentation of malaria infection in pregnant women in stable endemic areas are lacking,
and the few studies exploring this issue are unconclusive.
Methods: A prospective cohort of women followed monthly during pregnancy was conducted in three rural
dispensaries in Benin from August 2008 to September 2010. The presence of symptoms suggestive of malaria
infection in 982 women during antenatal visits (ANV), unscheduled visits and delivery were analysed. A multivariate
logistic regression was used to determine the association between symptoms and a positive thick blood smear
(TBS).
Results: During routine ANVs, headache was the only symptom associated with a higher risk of positive TBS (aOR
= 1.9; p < 0.001). On the occasion of unscheduled visits, fever (aOR = 5.2; p < 0.001), headache (aOR = 2.1; p =
0.004) and shivering (aOR = 3.1; p < 0.001) were significantly associated with a malaria infection and almost 90% of
infected women presented at least one of these symptoms. Two thirds of symptomatic malaria infections during
unscheduled visits occurred in late pregnancy and long after the last intermittent preventive treatment dose (IPTp).
Conclusion: The majority of pregnant women were symptomless during routine visits when infected with malaria
in an endemic stable area. The only suggestive sign of malaria (fever) was associated with malaria only on the
occasion of unscheduled visits. The prevention of malaria in pregnancy could be improved by reassessing the
design of IPTp, i.e. by determining an optimal number of doses and time of administration of anti-malarial drugs.
Background
In sub-Saharan Africa, 30 million women become preg-
nant each year [1]. Consequences of malaria in preg-
nancy (MiP) are a threat both to these mothers and to
their newborns. MiP increases the risk of maternal anae-
mia, and of low birth weight (LBW) [2,3]. LBW is the
single most important determinant of mortality during
the first year of life in African infants [4]. It has been
estimated that between 75,000 and 200,000 newborn
deaths occur each year as a direct result of LBW due to
malaria in pregnancy [1,4,5].
To prevent the consequences of MiP, the WHO
recommends an intermittent preventive treatment dur-
ing pregnancy (IPTp), an adequate management of clini-
cal malaria, and the use of insecticide-treated nets. IPTp
consists in the administration of two curative doses of
sulphadoxine/pyrimethamine (SP), at least four weeks
apart and beginning at the quickening[1], regardless to
the women’s malaria status. It is generally agreed that in
high transmission areas, pregnant women have acquired
a partial immunity to the disease and when infected
they present no or few symptoms[6-8]. Therefore, even
if the women remain asymptomatic and do not get a
curative treatment or do not attend frequently antenatal
visits (ANV), it is likely that SP IPTp has a long acting
prophylactic effect which protects them for the duration
of the pregnancy [9].
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presentation of malaria infection in pregnant women in
stable endemic areas are lacking, and only a limited
number of studies have focused on this issue[10-12].
Consequently, there is a need to ascertain throughout
pregnancy whether in malar i ah i g h l ye n d e m i ca r e a s ,
infected pregnant women are really asymptomatic or
not, and if there are symptoms, to evaluate their actual
incidence and intensity.
The STOPPAM project (Stategy TO Prevent Preg-
nancy Associated Malaria) consists in a prospective
cohort of 1000 pregnant women in Benin. This longitu-
dinal follow-up offered us the unique opportunity to
assess the clinical presentation of infected women dur-
ing the whole duration of pregnancy.
Methods
The STOPPAM project has been conceived to study the
underlying immunopathological processes causing poor
outcomes in MiP, through the characterization and
measurements of antibody and cellular immunological
responses during pregnancy, at delivery and during the
infant’s first year of life.
In this study, 1,000 pregnant women were followed-up
in each of two sites: Benin and Tanzania. Specifically in
Benin, 200 newborns to these mothers were followed-up
during their first year of life to investigate the immuno-
logical responses in the infants.
Study area, population
The study took place in the Mono province, located 70
km west of the economical capital of Benin, Cotonou. It
is a high transmission area, with two peaks during the
rainy seasons: from April to June, and from September
to November. The entomological inoculation rate is 35-
60 infective bites per person and per year [13]. Three
dispensaries were involved: Come, Akodeha and Oue-
deme Pedah, 10 km away from each other. Come is a
semi-rural area and the two other health centres are
located in a more rural surrounding. The principal
occupations of the inhabitants are farming, fishing and
trading.
There are one district hospital (which is the referral
hospital for the study), three government-run health dis-
pensaries and 11 private clinics in the study area. Five
nurses have been recruited and trained as “project assis-
tants” to fill questionnaires and to collect blood samples
from the study participants. Local midwives, nurses in
charge of the health centre and the project assistants
worked in close collaboration.
Study design
Pregnant women meeting the following criteria: gesta-
tional age under 24 weeks, living for more than six
months within 15 km from the dispensary and having
planned to deliver at the hospital, were enrolled in the
study after giving informed consent. At the initial visit
(identified as antenatal visit (ANV) 0), the assistants and
the midwives collected information regarding the repro-
ductive and the current pregnancy histories, medical
history, socio-economic indicators, and the use of bed
nets.
At each monthly ANV, axillary temperature and blood
pressure, weight, height and mid-upper arm circumfer-
ence were measured. After clinical examination, rapid
diagnostic tests (RDT) (Parascreen*, Zephyr Biomedical
Systems), thick and thin blood smears were systemati-
cally made to determine malaria infection. Any time
during the follow-up, women were invited to attend
health facilities in case of clinical symptoms to get care.
The same clinical and biological information were col-
lected as during ANVs. These visits were identified as
“unscheduled visits”.
On all occasion during follow-up (ANVs, unscheduled
visits or delivery), symptoms were actively asked by the
midwives in the private examination room following a
standardized questionnaire. The symptoms included:
headache, fever, stomach ache, nausea or vomiting, fever
in the last 48 hours, shivering.
Following the national guidelines, for IPTp two doses
of SP (1500 mg sulphadoxine and 75 mg pyrimetha-
m i n e )w e r ea d m i n i s t e r e da tl e a s to n em o n t ha p a r td u r -
ing the second trimester of pregnancy under the
supervision of midwives during antenatal visits. During
the follow-up, a malaria infection was defined as a posi-
tive RDT and fever was defined as an axillary tempera-
ture above or equal to 37.5°. Following the national
guidelines, all participants with malaria parasitaemia as
detected by RDT received a treatment dose of quinine
(24 mg/kg during 7 days), or SP if they were supposed
to receive the scheduled dose on the same visit.
Four ultrasound scans were performed from inclusion
until delivery: the first to determine the exact term of
the current pregnancy and the following to evaluate
intrauterine growth and foetal morphology. At delivery,
temperature, weight and blood pressure of the mother
were measured. Venous blood samples for biological
investigations, thick and thin blood smears and a RDT
were obtained before delivery. The newborn child was
fully examined.
Laboratory procedures
Thick blood smears (TBS) were stained with Giemsa
and read by two experienced parasitology technicians.
Smears were considered negative if no asexual-stage
Plasmodium parasite was detected after 500 leucocytes
had been counted. Malaria parasites were counted
against 200 leukocytes and parasite densities were
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results were discrepant, the slides were read by a third
microscopist.
For statistical analyses, malaria infection was defined
as parasitaemia detected by thick blood smear. Geo-
metric means were used to calculate average
parasitaemias.
This study was approved by the ethics committees of
the Research Institute for Development (IRD) in France
and of the Science and Health Faculty (University of
Abomey Calavi) in Benin. Written informed consent
was obtained from all participants.
Statistical analysis
Data were double-entered, validated and cleaned using
Access (Microsoft, version 2007). Stata version 10 for
Windows (Stata Corp, College Station, TX, USA) was
used for all statistical analyses. There were two sorts of
missing data to deal with: missing symptoms for the
f i r s ti n c l u d e dw o m e na n dm i s s i n gm a l a r i as t a t u sa t
delivery, essentially because of public health worker’s
strike. First, the characteristics between the mothers
with and without symptoms during first ANVs on one
hand and the ones with and without malaria status at
delivery on the other hand, were compared to ensure
they were similar.
Also, for the women whose symptoms were missing,
the multiple imputation by chained equation method
(MICE) based on the Gibbs algorithm was used and
then the stability of the results was checked with and
without MICE. Twenty imputed data sets were carried
out with 15 iterations for each.
For missing malaria status, a sensitivity analysis was
performed to ensure that the results remained the same,
and thus these missing data would not induce a bias.
Differences in proportions and means were compared
using the khi2 (or Fisher’s exact test) and the Student t-
test, respectively. A multivariate logistic regression was
used to determine the association between signs and
symptoms with positive malaria status at each visit. Cov-
ariates were included in the initial models only if the p-
v a l u ew a s<0 . 2i nt h eu n i v a r i a t ea n a l y s i s .I nt h ef i n a l
multivariate analysis, a p-value < 0.05 was considered
significant.
Results
F i g u r e1s h o w st h ef l o wo fw o m e nt h r o u g ht h es t u d y .
1,037 women were enrolled and 55 were excluded (38
withdrawals and 17 non pregnant women). 70 women did
not complete their pregnancy for medical reasons (four
maternal deaths, 32 stillbirths, 33 miscarriages and one
abortion) and 76 were lost to follow-up. The 76 women
982 women followed-up
>=3 ANVs attended : 
863 women
>=5 ANVs attended : 
538 women
818 live singletons 
18 live twins
-4 maternal deaths
-33 miscarriages (including 1 twin)
-32 stillbirths (including 2 twins)
-1 abortion for malformation
-15 house removals
-61 lost of follow-up: unstated reason
1037 women enrolled
-17 non pregnant women 
-38 withdrawals 
Figure 1 Study profile.
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frame and, therefore, outcomes of deliveries were
unknown. 836 women were known to have given birth,
however 128 TBS had not been performed due to a public
health-workers’ strike, and malaria status was not available
for these women. Nevertheless, age, gravidity, education
were similar between women with available TBS at deliv-
ery and those without; and between women followed-up
and women lost to follow-up.
Table 1 shows the general characteristics of the
mothers. On average mothers were 26.4 years old (range
15-45). Among the 982 followed-up women, 179 (18.2%)
were primigravidae. At enrolment, the mean gestational
age was 17.2 weeks (standard deviation (sd) = 4.7) with
a minimum of five weeks. 32.0% of women reported the
possession of bed nets at enrolment. Five hundred
twenty nine women attended unscheduled visits at least
once. The mean numbers of antenatal visits and
unscheduled visits were 4.4 (sd = 1.6) and 0.8 (sd = 0.9)
respectively and reached a maximum of eight and five
visits, respectively.
The overall prevalence of malaria infections was 10.2%
(602/5909). During the whole follow-up, primigravidae
had more peripheral infections than multigravidae
(15.0% vs 9.2%; p < 0.001). At the initial ANV (prior to
treatment and IPTp), the prevalence of malaria infec-
tions for primigravidae, secundigravidae and multigravi-
dae were 30.7%, 18.7% and 11.7%, (p < 0,001),
respectively.
Table 2 displays the signs and symptoms presented by
the mothers at ANVs, unscheduled visits and delivery,
and the multivariate analysis of factors associated with a
positive TBS at each visit.
As the STOPPAM project was not originally designed
to assess malaria clinical presentation during pregnancy,
the first 126 included women were not asked about
symptoms. Symptoms during first ANVs were thus lack-
ing for these women. To deal with these missing data,
the MICE method based on the Gibbs algorithm was
used.
During ANVs (including enrolment), among the 982
women initially followed-up, 307 were infected at least
once. Women under 25 (39.6% vs 25.6%; p < 0.001) and
primigravidae (43.0% vs 28.6%; p < 0.001) had a higher
risk of peripheral malaria infections than older women
and multigravidae, respectively.
On a total of 4,357 visits, 397 malaria infections were
found (table 2). Considering the total number of ANV,
the only clinical symtpom significantly associated with a
higher risk of positive TBS was headache (aOR = 1.9; p
< 0.001). Fever was also associated with malaria infec-
tion in univariate analysis (p = 0.003), but this associa-
tion was not significant anymore in multivariate analysis
(aOR = 1.6; p = 0.069). The intake of SP was protective
(aOR = 0.6; p < 0.001) and to not use bed nets was at
higher risk of malaria infection (aOR = 1.4; p = 0.003).
Among the 397 malaria infections occurring during
ANVs, headache was reported in 97 cases.
Among the 524 women who consulted during
u n s c h e d u l e dv i s i t s ,1 1 4w e r ei n f e c t e da tl e a s to n c e .
Young age of the woman was a risk factor to develop a
parasitaemia (26.4% vs 19.2%; p = 0.05).
On a total of 826 unscheduled visits, 130 malaria
infections were found (table 2): 99 women were infected
once, 14 women twice and one woman thrice. Consider-
ing the total number of unscheduled visits, fever (aOR =
5.2; p < 0.001), headache (aOR = 2.1; p = 0.004), and
shivering (aOR = 3.1; p < 0.001) were significantly asso-
ciated with a malaria infection during unscheduled vis-
its. One hundred and sixteen of the 130 malaria
episodes occurred with one or more of these symptoms,
which represents 89% of the malaria infections during
unscheduled visits.
Analyses were performed with and without MICE
method and the results remained unchanged.
At delivery, 71 women were infected with malaria and
fever and headache were significantly more frequent in
positive TBS mothers (aOR =3.6; p =0.001 and aOR
=3.6; p =0.029 respectively, table 2). A sensitivity analy-
sis was performed to ensure that the results remained
the same, and thus these missing data would not induce
a bias.
In addition, considering any symptom associated to
malaria infection, the mean parasitaemia of symptomatic
malaria infections was much higher during unscheduled
Table 1 General characteristics of the mothers
Factor Mean (SD) or N
(%)
Age (years) 26.4 (6.2)






> 2 584 (59.5%)





Number of ANVs 4.4 (1.6)
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Page 4 of 8Table 2 Factors associated with malaria infection (assessed by thick blood smear) during antenatal visits, unscheduled
visits and at delivery
Observed Univariate analysis Multivariate analysis after
MICE**
Malaria infected n (%) No malaria infected n(%) p-value Adjusted OR [95% CI] p-value
Antenatal visits
Fever No 374 (94.2) 3842 (97.0) 0.003*
Yes 23 (5.8) 118 (3.0)
Headache No 239 (71.1) 2907 (81.8) < 0.001* 1.9 [1.3-2.6] < 0.001*
Yes 97 (28.9) 648 (18.2)
Nausea No 323 (96.1) 3444 (96.9) 0.438
Yes 13 (3.9) 110 (3.1)
IPT 0 dose 256 (64.5) 1434 (36.2) < 0.001* 0.6 [0.5-0.7] < 0.001*
1 dose 39 (9.8) 840 (21.2)
2 doses 102 (25.7) 1685 (42.6)
Rainy season No 207 (52.1) 2150 (54.3) 0.412
Yes 190 (47.9) 1810 (45.7)
Bed net use No 221 (55.7) 1450 (36.6) < 0.001* 1.4 [1.1-1.8] 0.003*
Yes 176 (44.3) 2510 (63.4)
Unscheduled visits
Fever No 66 (50.8) 616 (88.5) < 0.001* 5.2 [3.2-8.1] < 0.001*
Yes 64 (49.2) 80 (11.5)
Headache No 24 (18.5) 352 (50.7) < 0.001* 2.1 [1.3-3.6] 0.004*
Yes 106 (81.5) 342 (49.3)
Nausea No 109 (83.9) 605 (87.1) 0.326
Yes 21 (16.1) 90 (12.9)
Feverishness in the last 48 hrs No 54 (41.5) 498 (72.6) < 0.001*
Yes 76 (58.5) 188 (27.4)
Shivering No 59 (45.4) 567 (81.6) < 0.001* 3.11 [2.0-4.9] < 0.001*
Yes 71 (54.6) 128 (18.4)
IPT 0 dose 33 (25.4) 140 (20.1) 0.058
1 dose 15 (11.5) 138 (19.8)
2 doses 82 (63.1) 418 (60.1)
Rainy season No 70 (53.9) 414 (59.5) 0.231
Yes 60 (46.1) 282 (40.5)
Bed net use No 33 (25.4) 193 (27.7) 0.582
Yes 97 (74.6) 503 (72.3)
Delivery
Primigravidae No 54 (76.1) 537 (84.3) 0.076
Yes 17 (23.9) 100 (15.7)
Age under 25 No 38 (53.5) 384 (61.4) 0.196
Yes 33 (46.5) 241 (38.6)
Fever No 59 (83.1) 601 (94.4) < 0.001* 3.6 [1.7-7.7] 0.001*
Yes 12 (16.9) 36 (5.7)
Headache No 63 (92.7) 610 (98.2) 0.004* 3.6 [1.1-11.6] 0.029*
Yes 5 (7.3) 11 (1.8)
Nausea No 66 (97.1) 609 (98.1) 0.576
Yes 2 (2.9) 12 (1.9)
Rainy season No 38 (53.5) 360 (56.5) 0.630
Yes 33 (46.5) 277 (43.5)
Bednet use No 13 (18.3) 113 (17.7) 0.905
Yes 58 (81.7) 524 (82.3)
* Statistically significant results (p < 0.05).
** adjusted on women’s characteristics (parity and age).
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Page 5 of 8visits than during ANVs (3641 parasites/μL vs 420 para-
sites/μL; p < 0.001).
Based on the pharmacokinetic properties of SP,[14] we
analysed the occurrence of malaria infections during
unscheduled visits in relation to a presumed SP efficacy
period of two months for each subject. 67% of malaria
infections occurred when the last dose of SP had been
given at least two months before (67% vs 33%, p <
0.001). As shown in Figure 2, two thirds of the sympto-




According to what has been generally described in
stable endemic areas, the majority (60%) of pregnant
women who were followed-up in the STOPPAM project
were asymptomatic when infected, although some of
them displayed clinical signs. During ANVs, 5% of the
infected women were febrile; but only headache, a non-
specific symptom, was significantly associated with a
higher risk of having a peripheral infection. However, its
frequency was moderate (28.9% of the malaria infec-
tions). In contrast, during unscheduled visits, Almost
90% of the malaria episodes were symptomatic and fever
(nearly half of the parasitized women), headache and
shivering were strongly associated with malaria
parasitaemia.
In high transmission areas pregnant women still have
an immune protection, and only exhibit limited symp-
toms when they get infected by malaria parasites[6-8].
Therefore, only a limited number of studies focused on
these issues and their results were often inconclusive. A
cross-sectional study conducted in Mozambique, limited
pregnant women consulting with clinical complaints
found that three quarters of them exhibited symptoms
suggestive of malaria, although only one quarter of them
were parasitaemic [10]. Another study in Nigeria also
found a very low specificity of fever in the prediction of
malaria infection in pregnant women [11].
A third study carried out in Ghana reported that MiP
was often symptomatic when women were actively
asked for clinical complaints[12]. All women attending
the antenatal clinics were screened for malaria without
distinction between scheduled or unscheduled visits.
Malaria infected women were enrolled into a rando-
mized controlled trial and women showing no malaria
parasitaemia were selected as a control group. However,
because of the case-control design of this study, and the
lack of blinding on the disease (presence of parasites in
peripheral blood), there may have been a risk of over-
reporting of these symptoms.
The STOPPAM project was able to offer women both
prospective routine ANVs and unscheduled visits in
case of clinical complaints. Also, symptoms and signs
were actively asked by midwives before TBS were per-
formed. Therefore, it was not prone to selection biases
unlike the abovementioned studies. Our results show
that the majority of infected pregnant women in this
stable malaria area only have few and mild clinical signs
during routine visits. Unscheduled visits are frequently
motivated by malaria-associated acute symptoms, parti-
cularly at distance from IPTp intakes. These women are
important to identify and to treat, in order to avoid
adverse consequences of MiP on the newborn child.
 
Figure 2 Distribution of symptomatic malaria infections during unscheduled visits.
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symptoms for the first women included were an issue to
deal with. First, gestity, age and education were shown
not to be different between the women with missing
data and the remaining women. Then, the MICE
method for these missing data was used and all results
remained similar using the MICE method or not. There-
fore, missing data related to symptoms were unlikely to
have induced a bias, and then to have altered the results.
For the delivery, malaria status was missing for 140
women who were thus excluded from the analysis.
Characteristics between excluded and remaining women
were similar and the sensitivity analysis performed
ensured that the results were similar. Moreover, the rea-
son for excluding these women (health worker’ss t r i k e )
could not possibly influence malaria status at delivery.
Consequently, the mechanism of missing data could not
have altered the results and induced a selection bias.
According to the few pharmacokinetic studies avail-
able, the SP blood concentration effective against a sen-
sitive Plasmodium isolate appears not to last over two
months in non-pregnant women [9,14], hence this dura-
tion was chosen as an estimate of the efficacy of SP. In
pregnant women, the pharmacokinetics of drugs are
modified due to an expanded volume of distribution,
and the duration of efficacy may actually be shorter. In
Benin, in vivo resistance rates to SP up to 50% have
been evidenced in children in a neighbouring area to
our study [15]. Even considering a hypothetical long
duration of efficacy, more than two thirds of malaria
infections we observed in this study occurred on the
occasion of unscheduled visits when SP could not be
considered efficacious any more, mostly at the end of
the pregnancy. As the foetal growth is more important
during the last trimester, these infections could be the
most deleterious for the foetus.
To avoid such late infections, different options could
be considered to offer pregnant women a better protec-
tion. In sub-Saharan Africa, the attendance to ANVs is
rather high: almost 70% of women attend at least once,
95% of them attend twice and more than half attend
four times[1,16]. The WHO recommends four ANVs
during pregnancy including three after quickening[1].
To improve the IPTp strategy, a possibility would be to
space out the interval between two SP doses. A first
dose could be given at the first ANV after quickening
and a second dose at least eight to 10 weeks later,
instead of the recommended space of one month.
Another option to improve the coverage of IPTp is to
give a third dose of SP. This strategy is currently recom-
mended for HIV-positive pregnant women, but few stu-
dies have evaluated the benefits of increasing the
number of SP administrations in HIV-negative women
[17-19]. Besides, safety information on the consequences
of increasing number of SP doses are lacking, as it could
also widespread resistance to the drug. It has been
documented that the administration of SP through IPTi
to infants in high transmission areas has little impact on
the resistance[20,21]. One can assume that the use of SP
in pregnant women, which is a smaller population than
infants, would have minor consequences. A clinical trial
is currently ongoing in Mali (A. Dicko, personal com-
munication) and thus should bring valuable information
on the subject.
Conclusion
This study found that pregnant women infected with
Plasmodium only had symptoms related to malaria
when infection was detected at unscheduled visits, gen-
erally at distance from the last dose of IPTp. A third
dose of IPTp administered at the end of pregnancy
might avoid such late infections. An alternative to SP-
IPTp in endemic areas where malaria incidence is
declining or SP resistance is high, could be an “intermit-
tent screening and treatment”, especially in areas with
high seasonal transmission, which consists in screening
all pregnant women during ANVs with RDTs and to
treat only malaria infected women.
Acknowledgements and funding
We are grateful to all the women who participated in the study. We thank
all the medical, laboratory, and administrative staffs of Akodeha, Come
central, Oudeme pedah Health centers and Hôpital de Zone for their
valuable contribution. We would particularly like to thank Jacqueline
Affedjou, Jean-Claude Sagbo, Marcel Ahlonsou, Bernadette Gandonou,
Gbetognon Hounguevou, Clément Massenon and Séverin Tossou-Vignibe
who were the field investigators, for their hard work and dedication to this
study. We also thank Pr. René Xavier Perrin for his useful advices and help
particularly for the ultrasound part of the study. We thank Franck
Noumbissie for the management of the project, and John Lusingu, Adrian JF
Luty, Thor Theander, Marita Troye-Blomberg, Nicaise Tuikue Ndam for their
contribution to the design of the study. We also thank Sébastien
Dechavanne for his work to the implementation of the study in the field.
We would like to thank for their financial support ExxonMobil and the GSK
foundation (BTH funding).
This paper describes work undertaken in the context of the STOPPAM
project, ‘Strategies To Prevent Pregnancy Associated Malaria’ (http://www.
stoppam.org). STOPPAM is a Small & Medium Scale Collaborative Project
supported by the European 7th Framework Programme, contract number:
200889”
Author details
1IRD/UMR 216 - Mère et enfant face aux infections tropicales, Faculté des
sciences pharmaceutiques - 4 avenue de l’Observatoire, 75270 Paris cedex
06, France.
2Université Paris Descartes, Faculté des sciences pharmaceutiques
- 4 avenue de l’Observatoire, 75270 Paris cedex 06, France.
3Hôpital de
Comé, BP 294 Comé, Bénin.
4Faculté des Sciences de la Santé (FSS), UER de
Parasitologie, Université de Cotonou 01BP188, Cotonou, Bénin.
Authors’ contributions
BTH carried out the acquisition, the statistical analysis and the interpretation
of data and drafted the manuscript. NF participated in the design and the
coordination of the study, the acquisition of data and revised critically the
manuscript. GB and SB participated in the acquisition of data. BGM and AM
participated in the design of the study and revised critically the manuscript.
PD coordinates the STOPPAM project, he participated in the design of this
Huynh et al. Malaria Journal 2011, 10:72
http://www.malariajournal.com/content/10/1/72
Page 7 of 8study and revised critically the manuscript. MC participated in the design
and the coordination of the study and supervised the writing of the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 2 November 2010 Accepted: 31 March 2011
Published: 31 March 2011
References
1. World Health Organization: A strategic framework for malaria prevention
and control during pregnancy in the African Region. WHO, Geneva; 2004,
AFR/MAL/04/01.
2. Brabin BJ: An analysis of malaria in pregnancy in Africa. Bull World Health
Organ 1983, 61(6):1005-1016.
3. Guyatt HL, Snow RW: The epidemiology and burden of Plasmodium
falciparum-related anemia among pregnant women in sub-Saharan
Africa. Am J Trop Med Hyg 2001, 64(1-2 Suppl):36-44.
4. McCormick MC: The contribution of low birth weight to infant mortality
and childhood morbidity. N Engl J Med 1985, 312(2):82-90.
5. Steketee RW, Nahlen BL, Parise ME, Menendez C: The burden of malaria in
pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001, 64(1-2
Suppl):28-35.
6. McGregor IA: Epidemiology, malaria and pregnancy. Am J Trop Med Hyg
1984, 33(4):517-525.
7. Nosten F, Rogerson SJ, Beeson JG, McGready R, Mutabingwa TK, Brabin B:
Malaria in pregnancy and the endemicity spectrum: what can we learn?
Trends Parasitol 2004, 20(9):425-432.
8. Steketee RW, Wirima JJ, Slutsker L, Khoromana CO, Heymann DL,
Breman JG: Malaria treatment and prevention in pregnancy: indications
for use and adverse events associated with use of chloroquine or
mefloquine. Am J Trop Med Hyg 1996, 55(1 Suppl):50-56.
9. White NJ: Intermittent presumptive treatment for malaria. PLoS Med 2005,
2(1):e3.
10. Bardaji A, Sigauque B, Bruni L, Romagosa C, Sanz S, Mabunda S,
Mandomando I, Aponte J, Sevene E, Alonso PL, Menendez C: Clinical
malaria in African pregnant women. Malar J 2008, 7:27.
11. Nnaji GA, Ikechebelu JI: An evaluation of the use of reported febrile
illness in predicting malaria in pregnancy. J Obstet Gynaecol 2007,
27(8):791-794.
12. Tagbor H, Bruce J, Browne E, Greenwood B, Chandramohan D: Malaria in
pregnancy in an area of stable and intense transmission: is it
asymptomatic? Trop Med Int Health 2008, 13(8):1016-1021.
13. Kelly-Hope LA, McKenzie FE: The multiplicity of malaria transmission: a
review of entomological inoculation rate measurements and methods
across sub-Saharan Africa. Malar J 2009, 8:19.
14. Watkins WM, Mberu EK, Winstanley PA, Plowe CV: The efficacy of antifolate
antimalarial combinations in Africa: a predictive model based on
pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997,
13(12):459-464.
15. Aubouy A, Fievet N, Bertin G, Sagbo JC, Kossou H, Kinde-Gazard D, Kiniffo R,
Massougbodji A, Deloron P: Dramatically decreased therapeutic efficacy
of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in
southern Benin. Trop Med Int Health 2007, 12(7):886-894.
16. Menendez C, D’Alessandro U, ter Kuile FO: Reducing the burden of
malaria in pregnancy by preventive strategies. Lancet Infect Dis 2007,
7(2):126-135.
17. Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD,
Steketee RW, Hamel M: Randomized trial of 2-dose versus monthly
sulfadoxine-pyrimethamine intermittent preventive treatment for
malaria in HIV-positive and HIV-negative pregnant women in Malawi. J
Infect Dis 2006, 194(3):286-293.
18. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R,
Oloo AJ, Steketee RW: Efficacy of sulfadoxine-pyrimethamine for
prevention of placental malaria in an area of Kenya with a high
prevalence of malaria and human immunodeficiency virus infection. Am
J Trop Med Hyg 1998, 59(5):813-822.
19. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL:
An evaluation of the effects of intermittent sulfadoxine-pyrimethamine
treatment in pregnancy on parasite clearance and risk of low
birthweight in rural Malawi. Ann Trop Med Parasitol 1998, 92(2):141-150.
20. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J,
Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E,
Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S,
Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B,
Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L,
Tanner M, Alonso P, Menendez C: Efficacy and safety of intermittent
preventive treatment with sulfadoxine-pyrimethamine for malaria in
African infants: a pooled analysis of six randomised, placebo-controlled
trials. Lancet 2009, 374(9700):1533-1542.
21. O’Meara WP, Smith DL, McKenzie FE: Potential impact of intermittent
preventive treatment (IPT) on spread of drug-resistant malaria. PLoS Med
2006, 3(5):e141.
doi:10.1186/1475-2875-10-72
Cite this article as: Huynh et al.: Malaria associated symptoms in
pregnant women followed-up in Benin. Malaria Journal 2011 10:72.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Huynh et al. Malaria Journal 2011, 10:72
http://www.malariajournal.com/content/10/1/72
Page 8 of 8